Corbus Pharmaceuticals Reports Q1 2026 Results: Advances in CRB-701 for Cancer and CRB-913 for Obesity, FDA Alignment, and Upcoming ASCO Data
Corbus Pharmaceuticals Reports Q1 2026 Results: Major Regula...
Sign in to continue:
Corbus Pharmaceuticals Reports Q1 2026 Results: Major Regula...
Definium Therapeutics Doses First Patient in Pivotal Ascend ...
Solésence, Inc. Reports Q1 Financial Results and Provides Bu...
AtaiBeckley Inc. Q1 2026 Financial Results and Business Upda...
Stratus Properties Inc. Q1 2026 Results and Strategic Update...
C3.ai (NYSE: AI) Announces Preliminary Q4 and FY2026 Results...
Alpha Modus Holdings, Inc. - Form 8-K Investor Update ...
SideChannel, Inc. FY 2026 Q2 Results: Revenue Drops, Margins...
Veradermics Q1 2026 Financial Results: Key Investor Takeaway...
USA TODAY Co., Inc. 8-K Filing: Key Details for Investors ...